Alico (ALCO) Q3 2023: Crop Insurance Proceeds Offset 51% Harvest Decline, Citrus Recovery Hinges on OTC Therapy

August 3, 2023 | By EarningsIQ Research

Hurricane Ian’s lingering impact drove a 51% drop in citrus harvest, but Alico’s insurance proceeds and disciplined land management kept liquidity robust. The company’s guarded optimism for next season is underpinned by maturing groves and the rollout of oxytetracycline trunk injections, though measurable benefits remain unproven until after the next harvest. Contract extensions with major buyers and falling input costs provide stability, but operational and weather risks remain heightened for the coming year.

Summary

• Insurance Windfall Buoys Cash Flow: Crop insurance proceeds covered hurricane-driven revenue shortfall, sustaining liquidity.
• Operational Reset Underway: Early adoption of oxytetracycline therapy and maturing groves set the stage for potential production recovery.
• Contract Laddering and Input Cost Relief: Renewed buyer contracts and easing fertilizer prices offer medium-term stability amid industry volatility.

Business Overview

Alico is a vertically integrated citrus grower and land management company, primarily generating revenue from the sale of oranges to juice processors, including long-term contracts with major brands like Tropicana. The business is organized around citrus production across roughly 49,500 Florida acres and land management, including ranch land sales and the optimization of real estate value. Ancillary services include grove management, though these have been scaled back following client exits from the citrus business.

Performance Analysis

Third quarter results were dominated by the aftershocks of Hurricane Ian, which drove a 51.4% year-over-year drop in citrus box production and a corresponding collapse in revenue. Operating revenue fell sharply as both box volume and fruit quality deteriorated, with internal fruit quality and pound solids per box down due to storm-induced fruit drop and accelerated harvesting. The company’s gross profit, excluding insurance proceeds, was materially compressed.

Offsetting this operational blow, Alico received $17.5 million in crop and property insurance proceeds in the quarter, with total insurance recoveries for the year reaching $21.4 million. Operating expenses fell on lower harvesting and caretaking activity, though per-box costs rose due to labor and the complexity of salvaging fruit post-storm. Land sales contributed $2.6 million in gains but were below prior-year levels. Adjusted EBITDA swung negative, reflecting the scale of the harvest decline and cost pressure, despite insurance inflows.

• Harvest Volume Collapse: Valencia box production down 49% versus USDA’s 55% state average decline, highlighting industry-wide disruption.
• Insurance Proceeds Critical: Insurance receipts, not core operations, drove positive net income, masking underlying weakness.
• Cost Structure Under Strain: Higher labor and input costs per box, despite lower total expense, signal ongoing margin headwinds.

Liquidity remains strong with $76.8 million undrawn credit, but the core citrus business faces a multi-season recovery trajectory as both tree maturity and therapeutic interventions play out.

Executive Commentary

Strategic Positioning

1. Citrus Recovery Hinges on OTC Therapy

Oxytetracycline (OTC), an antibiotic trunk injection therapy, is being deployed across 35% of Alico’s groves in hopes of mitigating citrus greening disease and reducing fruit drop. The therapy, newly approved in Florida, is low-cost (sub-$1 per tree per year) and is expected to improve fruit quality and yield, though measurable benefits will not be clear until after the 2023-2024 harvest. Early adoption positions Alico as a leader in industry recovery, but efficacy remains to be proven at scale.

2. Land Portfolio Optimization and Sales

Alico continues to monetize non-core ranch land, selling 1,436 acres year-to-date for $7.6 million in proceeds. The company is actively negotiating additional sales and working with land use planning professionals to maximize long-term real asset value. This provides optional liquidity and strategic flexibility, serving as a buffer during periods of operational volatility.

3. Contract Laddering and Price Visibility

Most fruit for the upcoming season is already under contract, with one Tropicana contract extended through 2024-2025 at improved pricing. The largest contracts expire after the next harvest, and management expects to negotiate renewals on shorter terms, reflecting industry caution. Stable pricing and volume commitments reduce near-term revenue risk, but renegotiation cycles could introduce volatility if industry conditions worsen.

4. Cost Management and Input Price Trends

Fertilizer and chemical prices are easing, providing some relief after years of inflation-driven cost increases. However, labor and fuel remain persistently high, and the company’s cost per box is elevated due to the labor intensity of harvesting post-storm fruit. Operational discipline is critical as the company navigates the lagging effects of inflation and seeks to restore margin structure.

Key Considerations

This quarter underscores the volatility inherent in agricultural production, especially in the face of severe weather events. With insurance proceeds providing a temporary backstop, the underlying business remains exposed to biological and market risks as it pursues recovery and growth.

Key Considerations:

• OTC Therapy Adoption: Early mover advantage if trunk injections deliver on yield and quality improvement, but benefits are unproven until next harvest.
• Land Monetization Optionality: Ongoing ranch land sales provide liquidity and downside protection, supporting balance sheet strength.
• Harvest Timing and Quality Risk: Accelerated harvesting to minimize fruit drop resulted in lower pound solids per box, impacting revenue per unit.
• Contract Structure Flexibility: Shorter-term contracts with major buyers allow for price resets but could introduce volatility if industry conditions shift.

Risks

Weather remains the dominant risk, with hurricane exposure and citrus greening disease posing ongoing threats to yield and tree health. Federal disaster relief remains uncertain, and any delays or shortfalls could strain recovery. Input cost volatility and labor constraints may continue to pressure margins, while contract renewals in a volatile market could reset pricing power. Land sales are opportunistic, but may not be sustainable as a long-term earnings lever.

Forward Outlook

For the next quarter, Alico offered no formal production or financial guidance, citing the need to await harvest progress in late fall. Management expects:

• Substantial increase in harvested fruit for 2023-2024 if grove health and OTC therapy deliver as hoped
• Stable pricing for contracted fruit, with most volume already committed for the next season

For full-year 2023, management did not provide explicit guidance, emphasizing:

• Guarded optimism for production recovery, but too early for quantification

Management highlighted several factors that will shape results:

• Extent of OTC therapy’s benefit will not be measurable until after the next harvest
• Continued land sales and real asset optimization expected to support liquidity

Takeaways

Alico’s near-term earnings are driven by insurance recoveries, not core operations, with a multi-year recovery path ahead as groves mature and new therapies are tested. Balance sheet strength and land monetization provide downside protection, but the core citrus business remains exposed to weather, disease, and input cost volatility.

• Insurance Proceeds Mask Underlying Weakness: Core citrus operations are not yet self-sustaining post-hurricane, with insurance and asset sales bridging the gap.
• Therapeutic Innovation Is a Key Swing Factor: Early OTC adoption could drive a production rebound, but efficacy must be proven at commercial scale.
• Watch for Contract Renewal Dynamics: Shorter-term contracts and industry volatility may reset pricing power in upcoming negotiations.

Conclusion

Alico’s Q3 demonstrates resilience through financial discipline and land management, but operational recovery will require successful biological interventions and favorable weather. Investors should monitor the efficacy of OTC therapy and contract renewal outcomes as the primary levers for future value creation.

Industry Read-Through

The Florida citrus industry’s 61% production collapse highlights systemic vulnerability to extreme weather and disease, with all major growers facing similar yield and quality headwinds. Adoption of oxytetracycline trunk injections is emerging as a potential industry-wide remedy for citrus greening, but broad efficacy and regulatory acceptance remain open questions. Land monetization and balance sheet flexibility are increasingly important for agricultural operators navigating biological risk, and may become a model for other specialty crop growers facing climate volatility. Contract laddering and shorter pricing cycles may also become more common as buyers and growers seek to manage risk in a turbulent supply environment.

ALCO Consumer Staples Agriculture Citrus Insurance Land Management Weather Risk Therapeutics